PROMIS PUBLICATIONS & ABSTRACTS

Clinical evidence from PROMIS


Evidence / Adjuvant / PROMIS

SABCS 2019: PROMIS Clinical Risk

AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Budway, Ellis Levine, Pat Whitworth, Blanche Mavromatis, Robin Zon, Sarah Untch1, Lisa Blumencranz, Joseph McKelley, William Audeh, PROMIS Investigators Group DESCRIPTION: Treatment recommendations in ER+ patients ≤ 50 years: comparison of the 21-gene assay and 70-gene signature in the PROMIS Read More

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Shelly Lo, MD; William Audeh, MD; Rubina Qamar, MD; Raye Budway, MD; Ellis Levine, MD; Pat Whitworth, MD; Blanche Mavromatis, MD; Robin Zon, MD; Dwight Oldham, MD; Sarah Untch, MS; Tina Treece, PhD; Lisa Blumencranz, PhD; Hatem Soliman, MD ABSTRACT: Read More